Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2339713 | 0.94 | MEN1 (0.41) | HIF1AEPAS1LMNASMN1; SMN2HTT | |
| SCHEMBL5668449 | 0.92 | MEN1 (0.40) | HIF1AEPAS1LMNASMN1; SMN2HTT | |
| SCHEMBL2338098 | 0.90 | ALDH1A1 (0.40) | HIF1AEPAS1LMNASMN1; SMN2HTT | |
| SCHEMBL2334778 | 0.90 | LMNA (0.41) | HIF1AEPAS1LMNASMN1; SMN2HTT | |
| SCHEMBL2338966 | 0.89 | MEN1 (0.42) | LMNASMN1; SMN2HTTTHRBKMT2A | |
| SCHEMBL2339348 | 0.89 | ALDH1A1 (0.43) | LMNASMN1; SMN2HTTTHRBKMT2A | |
| SCHEMBL2332022 | 0.87 | ALDH1A1 (0.39) | HIF1AEPAS1LMNASMN1; SMN2HTT | |
| SCHEMBL2332987 | 0.87 | MEN1 (0.41) | HIF1AEPAS1LMNASMN1; SMN2HTT | |
| SCHEMBL2332019 | 0.86 | HIF1A (0.45) | HIF1AEPAS1LMNASMN1; SMN2HTT | |
| SCHEMBL2335244 | 0.85 | TP53 (0.44) | LMNASMN1; SMN2ALDH1A1TAS2R14HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270902-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | claimed |
| EP-2360142-A1 | N-substituted benzene sulfonamides | Elan Pharmaceuticals Inc. (US) | 2011-08-24 | — | — | EP | claimed |
| EP-1723102-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | Elan Pharmaceuticals, Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| US-20050245573-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. | 2005-11-03 | — | — | US | claimed |
| WO-2005090296-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20120270902-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8193389-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2374792-A1 | N-substituted benzene sulfonamides | Elan Pharmaceuticals Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2360142-A1 | N-substituted benzene sulfonamides | Elan Pharmaceuticals Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-1723102-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | Elan Pharmaceuticals, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050245573-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005090296-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245573-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | HIF1A 2213/4885EPAS1 480/4885LMNA 3051/4885 |
| US-20120270902-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | HIF1A 2213/4885EPAS1 480/4885LMNA 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.